WegovyDirect and NovoCare Pharmacy: The Cash-Pay Wegovy Guide for 2026

The Direct Answer

NovoCare Pharmacy is Novo Nordisk's direct-to-consumer channel for Wegovy, launched on March 4, 2025. It ships every dose strength of brand-name Wegovy (semaglutide 2.4 mg) to self-paying U.S. patients for a flat $499 per month, no insurance required, as long as the patient holds a valid prescription from a licensed prescriber. Under the pricing agreement announced by the White House on November 6, 2025, Novo Nordisk committed to lowering that direct cash-pay price to $350 per month, rolling out through its direct channel and the government's TrumpRx platform during 2026. It is a different program from the Wegovy Savings Card, which requires commercial insurance.

One naming point up front: there is no official program called WegovyDirect. People use that shorthand by analogy with LillyDirect, Eli Lilly's equivalent self-pay channel for Zepbound. Novo Nordisk's program is named NovoCare Pharmacy and lives at novocare.com. Any third-party site branding itself as WegovyDirect is not the manufacturer's program, and that distinction matters when you are entering payment and medical information.

This guide covers how NovoCare Pharmacy works mechanically, who qualifies for the cash-pay price, how the savings card differs, how the program stacks up against LillyDirect, and where the compounded pathway sits relative to both.

How NovoCare Pharmacy Actually Works

Novo Nordisk announced NovoCare Pharmacy on March 4, 2025 as a direct home-delivery channel for self-paying patients. The launch did two notable things at once. First, it cut the company's cash offer for uninsured patients from the prior $650 per month to $499 per month. Second, and more importantly for anyone titrating upward, it applied one flat price to every dose strength, from the 0.25 mg starting dose through the 2.4 mg full maintenance dose. Before that, cash-pay pricing structures across the industry typically punished dose escalation.

The mechanics are simple. You need a valid Wegovy prescription from any U.S.-licensed prescriber; that can be your own physician, or a telehealth visit. You create an account at novocare.com, the prescription is routed to the program's dispensing pharmacy, you pay the flat monthly price directly, and the medication ships to your home in temperature-controlled packaging as standard prefilled pens. Refills recur monthly. No insurance claim is filed, no prior authorization is fought, and the purchase does not run through a pharmacy benefit.

For price context, Wegovy's published list price is $1,349.02 per 28-day supply. The list price is what the cash channel is designed to route around: it exists because a large share of commercial plans and nearly all state Medicaid programs restrict or exclude coverage of weight-loss medication, leaving list price as the default for millions of prescriptions that would otherwise go unfilled.

Novo Nordisk also plugged telehealth platforms into the channel. In April 2025 it announced collaborations that let Ro, Hims & Hers, and LifeMD bundle the prescribing visit with NovoCare fulfillment at the same $499 medication price. That arrangement did not stay intact: Novo Nordisk terminated the Hims & Hers collaboration in June 2025, publicly objecting to the platform's mass marketing of compounded semaglutide. The episode is worth knowing because it defines the fault line in this market, which is brand-name manufacturer channels on one side and the compounded pathway on the other.

Who Qualifies, and What Changed in November 2025

Eligibility for the cash-pay channel is deliberately broad. You qualify if you have a valid Wegovy prescription and you pay entirely out of pocket. That includes uninsured patients, insured patients whose plans exclude weight-loss drugs, and patients on Medicare or Medicaid who elect to purchase outside their benefit. The prescription itself is the gate: per FDA prescribing information, Wegovy is indicated for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition such as hypertension or type 2 diabetes, alongside diet and exercise, and in adolescents 12 and older meeting label criteria. A prescriber has to determine that you fit the label before any channel, cash or insured, will dispense.

The pricing floor moved in late 2025. On November 6, 2025, the White House announced an agreement under which Novo Nordisk and Eli Lilly committed to substantially lower direct cash-pay prices for their GLP-1 medications: for Novo Nordisk, that meant bringing Wegovy's direct price down to $350 per month through its own channel and through TrumpRx, the government's planned direct-purchase website, during 2026. Eli Lilly made a parallel commitment for Zepbound. Rollout has been phased, so treat $499 as the program's established baseline and $350 as the committed destination, and confirm the live price at your dose on novocare.com before you order.

Two practical cautions. First, cash payments through NovoCare Pharmacy generally do not count toward your insurance deductible or out-of-pocket maximum, because no claim is filed. If you are close to hitting a deductible on a plan that does cover Wegovy, running the prescription through insurance may beat cash even at a higher sticker price. Second, the flat price covers the medication; it does not include the prescriber visit, labs your clinician may want, or ongoing clinical follow-up, so budget the full journey rather than the vial-to-door price alone. Our roundup of the cheapest legal ways to get a GLP-1 online in 2026 maps total costs across every legitimate channel.

Cash Pay vs. the Wegovy Savings Card

The single most common confusion about Wegovy pricing is conflating NovoCare Pharmacy with the Wegovy Savings Card. They are different programs with nearly opposite eligibility rules.

The Wegovy Savings Card is an insurance copay offset. It requires commercial insurance, meaning employer-sponsored or marketplace coverage. If your commercial plan covers Wegovy, the card can reduce your copay to as little as $0 per 28-day supply, per Novo Nordisk's published offer terms, subject to monthly and annual benefit maximums. If you are enrolled in Medicare, Medicaid, TRICARE, or any other government program, federal anti-kickback rules make you ineligible for the card entirely, regardless of what you would be willing to pay.

NovoCare Pharmacy cash pay is the everything-else channel. No insurance is involved, so none of the card's restrictions apply. The trade-off runs the other way: because the purchase bypasses your benefit, a commercially insured patient with real Wegovy coverage will almost always do better with the card than with cash. The decision tree is short. Commercial insurance that covers Wegovy: use the savings card. Everyone else, including government-insured patients paying out of pocket: the cash channel is the manufacturer's price.

NovoCare Pharmacy vs. LillyDirect

Eli Lilly runs the mirror-image program for Zepbound, and the two are worth comparing directly because most cash-pay patients are choosing between these two medications, not between pharmacies.

On the medication question itself: in the STEP 1 trial published in the New England Journal of Medicine in 2021, adults on semaglutide 2.4 mg lost an average of 14.9 percent of body weight over 68 weeks versus 2.4 percent with placebo. In the SURMOUNT-1 trial, published in NEJM in 2022, tirzepatide at the highest dose produced an average 20.9 percent reduction over 72 weeks. Those were separate trials with different populations, so the comparison is directional, not head-to-head, and individual results vary with any GLP-1 medication. Dosing format matters too: LillyDirect's self-pay tier has historically shipped single-dose vials you draw up with a syringe, while NovoCare ships the standard prefilled pen at every dose. For the full breakdown of Lilly's program, including its dose-tier pricing history, see our LillyDirect Zepbound pricing guide.

Where the Compounded Pathway Fits

The manufacturer channels are one route to semaglutide. The other is compounded semaglutide, which contains the active ingredient in Wegovy and is prepared per individual prescription by a state-licensed 503A pharmacy; it is not itself FDA-approved as a drug. That regulatory distinction is the entire trade: brand-name Wegovy carries FDA approval of the finished product, while a compounded preparation is made for a specific patient under a prescriber's order and state pharmacy oversight rather than passing through FDA's drug-approval process.

The rules governing when 503A pharmacies may compound GLP-1 medications shifted after FDA declared the semaglutide shortage resolved in February 2025, and they continue to evolve; our 2026 update on FDA compounding rules tracks the current state. If you are weighing that pathway, start with the regulatory picture, then evaluate the specific pharmacy and clinical model behind any provider you consider. Our guide to whether compounded semaglutide is safe in 2026 lays out the questions worth asking, and our review of the best compounded GLP-1 providers compares how the major services handle pharmacy sourcing and physician oversight.

Trimi operates on that side of the line: licensed providers evaluate each patient and, when appropriate, prescribe compounded semaglutide or compounded tirzepatide, prepared per individual prescription by state-licensed 503A partner pharmacies. The clinical process is described step by step on our how it works page. Whether the brand channel or the compounded pathway fits you better depends on your budget, your insurance situation, and your clinician's judgment; the honest answer is that NovoCare Pharmacy is the strongest cash option Novo Nordisk has ever offered, and it should be in any self-pay patient's comparison set.

Frequently Asked Questions